Sign In

Antiretroviral Therapy.

HIV Question Bank

Antiretroviral Medications and Initial TherapyQuestion 6/10

Questions in Topic

A 26-year-old man was diagnosed with HIV 7 weeks prior. His initial laboratory studies showed an HIV RNA level of 108,656 copies/mL, a CD4 count 342 cells/mm3, positive hepatitis B surface antibody (HBsAb), and negative hepatitis B surface antigen (HBsAg). He missed his initial follow-up appointment to start antiretroviral therapy. Results from an HIV drug resistance genotype test are now available and show no resistance mutations. He has never taken HIV preexposure prophylaxis (PrEP).

Is this man a candidate to receive 2-drug therapy with dolutegravir-lamivudine?

Figure 1. GEMINI 1 and 2: Week 48 Results
Source: Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393:143-55.
Figure 2. GEMINI 1 and 2: Week 96 Results
Source: Cahn P, Madero JS, Arribas JR, et al. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. J Acquir Immune Defic Syndr. 2020;83:310-18.
Prev  Skip

Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
Question Last Updated
October 8th, 2024

Steps to Acquire CE for this Question Bank Topic:

1

Answer

Answer all questions
2

Score 80%+

Answer correctly
3

Claim CE

Choose CNE or CME
4

Give Feedback

Complete survey
5

Print Certificate

Obtain proof of CE

This question requires improvement because:


Comment further on how to improve this question or summary:



Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.